New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
New Phase 3 RAPID subgroup data show CARDAMYST (etripamil) nasal spray converted 66.7% of post-ablation PSVT patients to normal sinus rhythm within 30 minutes, versus 20% on placebo. The prior-ablation subgroup was small (N=11) and the analysis was descriptive and not powered for between-group comparison, though responses mirrored the broader RAPID efficacy population.
Key figures
- Drug Name
- CARDAMYST (etripamil) nasal spray
- Phase Of Trial
- Phase 3
- Subgroup size
- 11
- Trial total randomized
- 692
- Conversion rate placebo
- 20.0%
- Conversion rate etripamil
- 66.7%
- Prior ablation pct of randomized
- 6.6%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.